Study to Examine Clinical Performance and Safety of Cutimed® Gelling Fiber in Routine Clinical Practice

NCT ID: NCT05148390

Last Updated: 2024-02-21

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 36 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-04-24
• Study Completion Date: 2023-07-26

Brief Summary

This is a post - market study with a wound dressing, a CE-marked medical device available on the european market. The device will be used in routine clinical practice, i.e. within its intended purpose and without any additional invasive or stressing examinations for the patients.

Up to 36 adult patients with wounds suitable to be treated with the medical device and meeting the inclusion/exclusion criteria will be enrolled at two participating German sites.

During 5 on-site visits within 28 days routine weekly dressing changes the Health Care Professional will examine the wound and will perform required wound care and dressing changes. Pictures of the wound with and without dressing will be taken at each visit and used for automatic analysis. The subjects will be asked to rate their general wound pain and the pain perceived during dressing changes. A wound-related quality of life questionnaire will be presented to the subjects twice and the subject and HCP will rate their safisfaction with the product.

Detailed Description

This Post Market Clinical Follow up (PMCF) study will examine product features of the CE-marked wound dressing after having received market authorization regarding the fulfilment of predefined requirements for the successful management of skin integrity during wound care. The primary purpose of this study is to evaluate clinical safety and performance of the product when used on several wounds in routine wound care without any additional invasive or burdensome methods and within the intended use.

As primary objective the dressing´s absorption performance and its ability to prevent exudate accumulation in the wound will be investigated. Further, device disintegration, need of debridement, wound and skin conditions, treatment related pain, general wound pain, dressing adhesion and quality of life as well as Helath Care professional's (HCP´s) and patient´s satisfaction are considered as secondary outcomes.

In total, 36 eligible subjects will be enrolled at 2 German sites, including 15 % dropouts.

5 on-site visits are to be performed by the subjects in the scope of routine weekly wound care/dressing change visits during 28 days (Day 0, Day7, Day 14, Day21, Day28). The IMD will be applied during each on-site visit including wound care, wound examination/documentation and dressing change according to HCP's judgment and individual circumstances of the wound. Photographic documentation of the wound and the wound with applied dressings will be performed and used for further automatic wound/tissue analyis. General wound pain as well as pain perceived during dressing change will be documented, as well as Wound-related Quality of life as well as Patient's/HCP's satisfaction with the product.

Conditions

Leg Ulcer; Diabetic Foot Ulcer; Pressure Ulcer; Surgical Wound; Abrasion; Laceration; Burn, Partial Thickness; Oncology Wound

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Interventions

Cutimed® Gelling Fiber

application of dressing

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• mentally and physically able to participate in study
• written informed consent to participate in the study
• Diagnosed wound indicated for treatment with Cutimed® Gelling Fiber for 4 weeks (except for internal body cavities and closed wounds)
• Subjects with more than one ulcer are eligible for inclusion, however only one ulcer per subject will be included in the study.

Exclusion Criteria

• Sensitivity to or allergic reaction to the dressing or its components
• Participation in any other clinical study investigating drugs or medical devices
• Subjects presenting with wounds including internal body cavities or closed wounds
• Alcohol and drug addiction
• Pregnant or breast-feeding subjects
• Underlying diseases are not treated according to respective country-specific guidelines

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BSN Medical GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Arne Böhling, Dr.

Role: STUDY_DIRECTOR

BSN Medical GmbH

Locations

Christliches Klinikum Melle GmbH, Unfallchirurgie

Melle, , Germany

Countries

Germany

Other Identifiers

C2820

Identifier Type: -

Identifier Source: org_study_id